scholarly journals UPDATED SAFETY AND EFFICACY DATA IN THE PHASE 1 TRIAL OF PATIENTS WITH MANTLE CELL LYMPHOMA (MCL) TREATED WITH BRUTON TYROSINE KINASE (BTK) INHIBITOR ZANUBRUTINIB (BGB-3111)

2019 ◽  
Vol 37 ◽  
pp. 245-247 ◽  
Author(s):  
C.S. Tam ◽  
M. Wang ◽  
D. Simpson ◽  
S. Opat ◽  
G. Cull ◽  
...  
Keyword(s):  
Tyrosine Kinase ◽  
Mantle Cell Lymphoma ◽  
Cell Lymphoma ◽  
Phase 1 ◽  
Efficacy Data ◽  
Safety And Efficacy ◽  
Phase 1 Trial ◽  
Mantle Cell ◽  
Bruton Tyrosine Kinase ◽  
Btk Inhibitor

scholarly journals Egress of CD19+CD5+ cells into peripheral blood following treatment with the Bruton tyrosine kinase inhibitor ibrutinib in mantle cell lymphoma patients

Blood ◽  
2013 ◽  
Vol 122 (14) ◽  
pp. 2412-2424 ◽  
Author(s):  
Betty Y. Chang ◽  
Michelle Francesco ◽  
Martin F. M. De Rooij ◽  
Padmaja Magadala ◽  
Susanne M. Steggerda ◽  
...  
Keyword(s):  
Tyrosine Kinase Inhibitor ◽  
Mantle Cell Lymphoma ◽  
Peripheral Blood ◽  
Kinase Inhibitor ◽  
Cell Lymphoma ◽  
Key Points ◽  
Mantle Cell ◽  
Bruton Tyrosine Kinase ◽  
Btk Inhibitor ◽  
And Migration

Key Points MCL cells are mobilized into the peripheral blood of patients treated with the BTK inhibitor ibrutinib. Ibrutinib dose-dependently inhibits BCR- and chemokine-mediated adhesion and migration of MCL cells.

Bruton tyrosine kinase is commonly overexpressed in mantle cell lymphoma and its attenuation by Ibrutinib induces apoptosis

2013 ◽  
Vol 37 (10) ◽  
pp. 1271-1277 ◽  
Author(s):  
Munevver Cinar ◽  
FaridSaei Hamedani ◽  
Zhicheng Mo ◽  
Bekir Cinar ◽  
Hesham M. Amin ◽  
...  
Keyword(s):  
Tyrosine Kinase ◽  
Mantle Cell Lymphoma ◽  
Cell Lymphoma ◽  
Mantle Cell ◽  
Bruton Tyrosine Kinase
Sign in / Sign up

Export Citation Format

Share Document